Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Venous Thromboembolism 15Venous Thrombosis 11Pulmonary Embolism 10Neoplasms 9Thrombosis 4Thromboembolism 4Pancreatic Neoplasms 4Lung Neoplasms 4Multiple Myeloma 3Neoplasm Metastasis 2Lymphoma 2Hemorrhage 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Thrombophilia 1Thrombocytopenia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Ovarian Neoplasms 1Obesity 1Neoplasms, Plasma Cell 1

Interventions

Warfarin 1Dalteparin 14-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Embolism × Dalteparin × Clear all
NCT00216866 2017-08-28

The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Completed
70 enrolled

Embolism, Thrombosis, Embolism and Thrombosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡